Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial.

Miles FL, Goodman PJ, Tangen C, Torkko KC, Schenk JM, Song X, Pollak M, Thompson IM, Neuhouser ML.

Nutrients. 2017 Apr 12;9(4). pii: E378. doi: 10.3390/nu9040378.

2.

Does milk intake promote prostate cancer initiation or progression via effects on insulin-like growth factors (IGFs)? A systematic review and meta-analysis.

Harrison S, Lennon R, Holly J, Higgins JPT, Gardner M, Perks C, Gaunt T, Tan V, Borwick C, Emmet P, Jeffreys M, Northstone K, Rinaldi S, Thomas S, Turner SD, Pease A, Vilenchick V, Martin RM, Lewis SJ.

Cancer Causes Control. 2017 Jun;28(6):497-528. doi: 10.1007/s10552-017-0883-1. Epub 2017 Mar 30. Review.

3.

Prediagnostic circulating concentrations of plasma insulin-like growth factor-I and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition.

Perez-Cornago A, Appleby PN, Tipper S, Key TJ, Allen NE, Nieters A, Vermeulen R, Roulland S, Casabonne D, Kaaks R, Fortner RT, Boeing H, Trichopoulou A, La Vecchia C, Klinaki E, Hansen L, Tjønneland A, Bonnet F, Fagherazzi G, Boutron-Ruault MC, Pala V, Masala G, Sacerdote C, Peeters PH, Bueno-de-Mesquita HB, Weiderpass E, Dorronsoro M, Quirós JR, Barricarte A, Gavrila D, Agudo A, Borgquist S, Rosendahl AH, Melin B, Wareham N, Khaw KT, Gunter M, Riboli E, Vineis P, Travis RC.

Int J Cancer. 2017 Mar 1;140(5):1111-1118. doi: 10.1002/ijc.30528. Epub 2016 Dec 27.

4.

A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk.

Travis RC, Appleby PN, Martin RM, Holly JM, Albanes D, Black A, Bueno-de-Mesquita HB, Chan JM, Chen C, Chirlaque MD, Cook MB, Deschasaux M, Donovan JL, Ferrucci L, Galan P, Giles GG, Giovannucci EL, Gunter MJ, Habel LA, Hamdy FC, Helzlsouer KJ, Hercberg S, Hoover RN, Janssen JA, Kaaks R, Kubo T, Le Marchand L, Metter EJ, Mikami K, Morris JK, Neal DE, Neuhouser ML, Ozasa K, Palli D, Platz EA, Pollak MN, Price AJ, Roobol MJ, Schaefer C, Schenk JM, Severi G, Stampfer MJ, Stattin P, Tamakoshi A, Tangen CM, Touvier M, Wald NJ, Weiss NS, Ziegler RG, Key TJ, Allen NE; Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group.

Cancer Res. 2016 Apr 15;76(8):2288-300. doi: 10.1158/0008-5472.CAN-15-1551. Epub 2016 Feb 26.

5.

Isoflavone pharmacokinetics and metabolism after consumption of a standardized soy and soy-almond bread in men with asymptomatic prostate cancer.

Ahn-Jarvis JH, Clinton SK, Grainger EM, Riedl KM, Schwartz SJ, Lee ML, Cruz-Cano R, Young GS, Lesinski GB, Vodovotz Y.

Cancer Prev Res (Phila). 2015 Nov;8(11):1045-54. doi: 10.1158/1940-6207.CAPR-14-0465. Epub 2015 Aug 14.

6.

A pilot study to investigate if New Zealand men with prostate cancer benefit from a Mediterranean-style diet.

Erdrich S, Bishop KS, Karunasinghe N, Han DY, Ferguson LR.

PeerJ. 2015 Jul 2;3:e1080. doi: 10.7717/peerj.1080. eCollection 2015.

7.
8.

Adjusting for heritable covariates can bias effect estimates in genome-wide association studies.

Aschard H, Vilhjálmsson BJ, Joshi AD, Price AL, Kraft P.

Am J Hum Genet. 2015 Feb 5;96(2):329-39. doi: 10.1016/j.ajhg.2014.12.021. Epub 2015 Jan 29.

9.

Activation of various downstream signaling molecules by IGFBP-3.

Shahjee HM, Bhattacharyya N.

J Cancer Ther. 2014 Aug 1;5(9):830-835.

10.

Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma.

Cao Y, Roth M, Piperdi S, Montoya K, Sowers R, Rao P, Geller D, Houghton P, Kolb EA, Gill J, Gorlick R.

PLoS One. 2014 Aug 29;9(8):e106249. doi: 10.1371/journal.pone.0106249. eCollection 2014.

11.

Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study.

Sourbeer KN, Howard LE, Andriole GL, Moreira DM, Castro-Santamaria R, Freedland SJ, Vidal AC.

BJU Int. 2015 May;115(5):736-43. doi: 10.1111/bju.12843. Epub 2014 Oct 20.

12.

Novel tools for prostate cancer prognosis, diagnosis, and follow-up.

Dimakakos A, Armakolas A, Koutsilieris M.

Biomed Res Int. 2014;2014:890697. doi: 10.1155/2014/890697. Epub 2014 May 4. Review.

13.

Insulin-like growth factor pathway genetic polymorphisms, circulating IGF1 and IGFBP3, and prostate cancer survival.

Cao Y, Lindström S, Schumacher F, Stevens VL, Albanes D, Berndt S, Boeing H, Bueno-de-Mesquita HB, Canzian F, Chamosa S, Chanock SJ, Diver WR, Gapstur SM, Gaziano JM, Giovannucci EL, Haiman CA, Henderson B, Johansson M, Le Marchand L, Palli D, Rosner B, Siddiq A, Stampfer M, Stram DO, Tamimi R, Travis RC, Trichopoulos D, Willett WC, Yeager M, Kraft P, Hsing AW, Pollak M, Lin X, Ma J.

J Natl Cancer Inst. 2014 Jun;106(6):dju085. Erratum in: J Natl Cancer Inst. 2014 Jun;106(6):dju194.

14.

Targeting insulin-like growth factor 1 receptor inhibits pancreatic cancer growth and metastasis.

Subramani R, Lopez-Valdez R, Arumugam A, Nandy S, Boopalan T, Lakshmanaswamy R.

PLoS One. 2014 May 8;9(5):e97016. doi: 10.1371/journal.pone.0097016. eCollection 2014.

15.

Association of polymorphisms and haplotypes in the insulin-like growth factor 1 receptor (IGF1R) gene with the risk of breast cancer in Korean women.

Kang HS, Ahn SH, Mishra SK, Hong KM, Lee ES, Shin KH, Ro J, Lee KS, Kim MK.

PLoS One. 2014 Jan 2;9(1):e84532. doi: 10.1371/journal.pone.0084532. eCollection 2014. Erratum in: PLoS One. 2014;9(3):e91218.

16.

Variant NKX3.1 and Serum IGF-1: Investigation of Interaction in Prostate Cancer.

Muhlbradt E, Ma J, Severi G, Ortner E, Hayes V, Hoang HN, Stampfer M, Giles G, Pollak M, Gelmann EP.

Genes Cancer. 2013 Nov;4(11-12):535-45. doi: 10.1177/1947601913506009.

17.

Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study.

Zu K, Martin NE, Fiorentino M, Flavin R, Lis RT, Sinnott JA, Finn S, Penney KL, Ma J, Fazli L, Gleave ME, Bismar TA, Stampfer MJ, Pollak MN, Loda M, Mucci LA, Giovannucci E.

Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):1984-93. doi: 10.1158/1055-9965.EPI-13-0349. Epub 2013 Aug 27.

18.

Pleiotropy between genetic markers of obesity and risk of prostate cancer.

Edwards TL, Giri A, Motley S, Duong W, Fowke JH.

Cancer Epidemiol Biomarkers Prev. 2013 Sep;22(9):1538-46. doi: 10.1158/1055-9965.EPI-13-0123. Epub 2013 Jun 27.

19.

Insulin-like growth factor-1 genotypes and haplotypes influence the survival of prostate cancer patients with bone metastasis at initial diagnosis.

Tsuchiya N, Narita S, Inoue T, Saito M, Numakura K, Huang M, Hatakeyama S, Satoh S, Saito S, Ohyama C, Arai Y, Ogawa O, Habuchi T.

BMC Cancer. 2013 Mar 25;13:150. doi: 10.1186/1471-2407-13-150.

20.

Ligand-independent activation of MET through IGF-1/IGF-1R signaling.

Varkaris A, Gaur S, Parikh NU, Song JH, Dayyani F, Jin JK, Logothetis CJ, Gallick GE.

Int J Cancer. 2013 Oct 1;133(7):1536-46. doi: 10.1002/ijc.28169. Epub 2013 Apr 17.

Supplemental Content

Support Center